A Quantitative Concordance Measure for Comparing and Combining Treatment Selection Markers.

Area of Science:

• Biostatistics
• Precision Medicine
• Clinical Trial Methodology

Background:

• Precision medicine relies on treatment selection markers to personalize patient care.
• Current methods often dichotomize markers, limiting their utility due to factors like safety and cost.
• A statistical framework is needed to compare and combine markers without arbitrary cutoff values.

Purpose of the Study:

• To develop a statistical framework for comparing and combining treatment selection markers.
• To introduce a quantitative concordance measure for evaluating marker performance.
• To enable personalized treatment selection without marker dichotomization.

Main Methods:

• Proposed a quantitative concordance measure to assess marker-predicted treatment effects.
• Utilized U-statistics for estimating the concordance measure from clinical trial data.
• Incorporated auxiliary covariates via an augmentation term in the U-statistic.
• Developed a cross-validation procedure for optimizing marker combinations and mitigating bias.

Main Results:

• The proposed concordance measure effectively quantifies the predictive power of markers for treatment effects.
• The methodology was successfully applied to an HIV treatment selection example.
• Simulation studies demonstrated the robustness and utility of the proposed framework.

Conclusions:

• The developed statistical framework allows for effective comparison and combination of treatment selection markers.
• This approach supports more nuanced and personalized treatment decisions in precision medicine.
• The methodology offers a valuable tool for optimizing treatment strategies based on marker data.